Sep. 8 at 7:02 PM
$SVRA ".... (1) The completion of CMC work by early Q4 with drug supplier Fujifilm (+5-10% stock move) should trigger add'l catalysts, such as (2) a BLA acceptance in Q1:26 (+5-15% move), (3) AdCom in mid-2026 (perhaps +15-35%), and (4) PDUFA as early as Aug 2026..Mgmt's latest market research confirms the diagnosed US population could actually be 50% larger, prompting us to raise our peak sales estimate to
$500M (up from prior
$400M), which could still be conservative. Net-net,
$500M sales x high 4-5x multiple (biosimilar competition is unlikely) =
$2.0-2.5B valuation (up from
$800M+ cap)."